Tumor, Solid Clinical Trials

19 recruiting

Tumor, Solid Trials at a Glance

19 actively recruiting trials for tumor, solid are listed on ClinicalTrialsFinder across 6 cities in 9 countries. The largest study group is Phase 1 with 13 trials, with the heaviest enrollment activity in Beijing, Shanghai, and San Antonio. Lead sponsors running tumor, solid studies include Avelos Therapeutics Inc., Biorek S.R.L., and Aadi Bioscience, Inc..

Browse tumor, solid trials by phase

Treatments under study

About Tumor, Solid Clinical Trials

Looking for clinical trials for Tumor, Solid? There are currently 19 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Tumor, Solid trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Tumor, Solid clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 119 of 19 trials

Recruiting
Not Applicable

Standardized Nutritional Management of Pediatric Patients With Solid Tumors

Tumor, SolidChildrenNutritional Intervention
Children's Hospital of Fudan University400 enrolled1 locationNCT06730204
Recruiting
Phase 1Phase 2

TumorGlow Intraoperative Molecular Imaging (IMI)

Tumor, Solid
University of Pennsylvania500 enrolled1 locationNCT04723810
Recruiting
Phase 1Phase 2

Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor

Lung CancerPancreas CancerThyroid Cancer+1 more
Sichuan Enray Pharmaceutical Sciences Company54 enrolled9 locationsNCT07433283
Recruiting
Phase 1

Study of RGL-270 Single Drug and Combined With Adebelimab in Patients in Patients at High Risk of Recurrence After Radical Treatment of Malignant Solid Tumors

Tumor, Solid
Xian-Jun Yu198 enrolled1 locationNCT07348042
Recruiting

Immune Profiling for Cancer Immunotherapy Response

CancerHematologic MalignancyTumor, Solid+1 more
Dartmouth-Hitchcock Medical Center1,500 enrolled1 locationNCT06116032
Recruiting
Phase 1

T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor

Tumor, Solid
TingBo Liang9 enrolled1 locationNCT06478251
Recruiting
Phase 1

T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor

Tumor, Solid
Ting Deng9 enrolled1 locationNCT06484790
Recruiting
Phase 1

Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment

Advanced Solid TumorTumorTumor, Solid
Aadi Bioscience, Inc.28 enrolled2 locationsNCT05661461
Recruiting
Phase 1

Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Pancreatic CancerMelanomaTumor, Solid
UNC Lineberger Comprehensive Cancer Center45 enrolled1 locationNCT03454035
Recruiting
Phase 1

A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab

Advanced Solid TumorCancerMetastatic Cancer+2 more
Nectin Therapeutics Ltd90 enrolled6 locationsNCT05378425
Recruiting
Phase 1Phase 2

LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours.

Tumor, Solid
Leucid Bio17 enrolled2 locationsNCT06193902
Recruiting
Phase 1

T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor

Tumor, Solid
Tao Zhang9 enrolled2 locationsNCT06484556
Recruiting
Phase 2

Phase II Study of Intensity Modulated Radiotherapy in Dose Painting for Sinus Carcinomas After Endoscopic Surgery

Tumor, Solid
Centre Francois Baclesse52 enrolled3 locationsNCT05943119
Recruiting
Phase 1Phase 2

A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment

Tumor, Solid
Evopoint Biosciences Inc.132 enrolled1 locationNCT06987500
Recruiting
Phase 1Phase 2

AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors

Solid TumorSolid Tumor, AdultSolid Tumor Cancer+4 more
Avelos Therapeutics Inc.36 enrolled3 locationsNCT06911333
Recruiting
Phase 1Phase 2

A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

Advanced Solid TumorCancerNon-small Cell Lung Cancer+4 more
OncoResponse, Inc.168 enrolled4 locationsNCT06090266
Recruiting
Early Phase 1

A Study of Tumor Neoantigen-specific T Cells in the Treatment of Advanced Solid Tumors

Tumor, Solid
JIANG LONGWEI6 enrolled1 locationNCT06431529
Recruiting
Not Applicable

Comparison of FDG and FAPI in Patients With Various Types of Cancer

Tumor, Solid
The First Affiliated Hospital of Xiamen University3,000 enrolled1 locationNCT04416165
Recruiting

Biomarkers of Renal Cancer

Renal Cell CarcinomaTumor, SolidOncocytoma+1 more
Biorek S.R.L.1,000 enrolled4 locationsNCT05785052